Skip NavigationSkip to Content

HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection

  1. Author:
    Mens, H.
    Kearney, M.
    Wiegand, A.
    Shao, W.
    Schonning, K.
    Gerstoft, J.
    Obel, N.
    Maldarelli, F.
    Mellors, J. W.
    Benfield, T.
    Coffin, J. M.
  2. Author Address

    [Mens, Helene; Kearney, Mary; Wiegand, Ann; Maldarelli, Frank; Coffin, John M.] NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA. [Mens, Helene; Benfield, Thomas] Copenhagen Univ Hosp, Dept Infect Dis, Hvidovre, Denmark. [Mens, Helene; Benfield, Thomas] Copenhagen Univ Hosp, Clin Res Ctr, Hvidovre, Denmark. [Shao, Wei] NCI, ISP Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21702 USA. [Schonning, Kristian] Copenhagen Univ Hosp, Dept Clin Microbiol, Hvidovre, Denmark. [Gerstoft, Jan; Obel, Niels] Rigshosp, Dept Infect Dis, Copenhagen, Denmark. [Mellors, John W.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. [Coffin, John M.] Tufts Univ, Boston, MA 02111 USA.;Mens, H, NCI, HIV Drug Resistance Program, NIH, Bldg 535, Frederick, MD 21702 USA.;helene.mens@gmail.com
    1. Year: 2010
    2. Date: Dec
  1. Journal: Journal of Virology
    1. 84
    2. 24
    3. Pages: 12971-12981
  2. Type of Article: Article
  3. ISSN: 0022-538X
  1. Abstract:

    Elucidating mechanisms leading to the natural control of HIV-1 infection is of great importance for vaccine design and for understanding viral pathogenesis. Rare HIV-1-infected individuals, termed HIV-1 controllers, have plasma HIV-1 RNA levels below the limit of detection by standard clinical assays (<50 to 75 copies/ml) without antiretroviral therapy. Although several recent studies have documented persistent low-grade viremia in HIV-1 controllers at a level not significantly different from that in HIV-1-infected individuals undergoing treatment with combination antiretroviral therapy (cART), it is unclear if plasma viruses are undergoing full cycles of replication in vivo or if the infection of new cells is completely blocked by host immune mechanisms. We studied a cohort of 21 HIV-1 controllers with a median level of viremia below 1 copy/ml, followed for a median of 11 years. Less than half of the cohort carried known protective HLA types (B*57/27). By isolating HIV-1 RNA from large volumes of plasma, we amplified single genome sequences of both pro-rt and env longitudinally. This study is the first to document that HIV-1 pro-rt and env evolve in this patient group, albeit at rates somewhat lower than in HIV-1 noncontrollers, in HLA B*57/27-positive, as well as HLA B*57/27-negative, individuals. Viral diversity and adaptive events associated with immune escape were found to be restricted in HIV-1 controllers, suggesting that replication occurs in the face of less overall immune selection.

    See More

External Sources

  1. DOI: 10.1128/jvi.00387-10
  2. WOS: 000284469600049

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel